

# Andreas Roos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8162615/publications.pdf>

Version: 2024-02-01

66  
papers

1,107  
citations

471061

17  
h-index

500791

28  
g-index

69  
all docs

69  
docs citations

69  
times ranked

1657  
citing authors

#	ARTICLE	IF	CITATIONS
1	A <i>de novo</i> <i>CSDE1</i> variant causing neurodevelopmental delay, intellectual disability, neurologic and psychiatric symptoms in a child of consanguineous parents. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 283-291.	0.7	1
2	High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases. <i>Brain</i> , 2022, 145, 1507-1518.	3.7	14
3	Multispectral optoacoustic tomography for non-invasive disease phenotyping in pediatric spinal muscular atrophy patients. <i>Photoacoustics</i> , 2022, 25, 100315.	4.4	16
4	Novel insights into <i>PORCN</i> mutations, associated phenotypes and pathophysiological aspects. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 29.	1.2	3
5	Identification of a novel homozygous <i>synthesis of cytochrome c oxidase 2</i> variant in siblings with early-onset axonal Charcot-Marie-Tooth disease. <i>Human Mutation</i> , 2022, 43, 477-486.	1.1	3
6	<i>NCAM1</i> and <i>GDF15</i> are biomarkers of Charcot-Marie-Tooth disease in patients and mice. <i>Brain</i> , 2022, 145, 3999-4015.	3.7	12
7	Serum miRNAs as biomarkers for the rare types of muscular dystrophy. <i>Neuromuscular Disorders</i> , 2022, 32, 332-346.	0.3	5
8	Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy. <i>European Journal of Neurology</i> , 2022, 29, 2084-2096.	1.7	13
9	Circulating small RNA signatures differentiate accurately the subtypes of muscular dystrophies: small-RNA next-generation sequencing analytics and functional insights. <i>RNA Biology</i> , 2022, 19, 507-518.	1.5	1
10	Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. <i>Acta Neuropathologica</i> , 2022, 144, 353-372.	3.9	19
11	New Insights into the Neuromyogenic Spectrum of a Gain of Function Mutation in <i>SPTLC1</i> . <i>Genes</i> , 2022, 13, 893.	1.0	2
12	Endoplasmic reticulum stress and unfolded protein response activation in immune-mediated necrotizing myopathy. <i>Brain Pathology</i> , 2022, 32, .	2.1	7
13	Diagnosing X-linked Myotubular Myopathy – A German 20-year Follow Up Experience. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 79-90.	1.1	12
14	Expanding the clinical and molecular spectrum of <i>ATP6V1A</i> related metabolic cutis laxa. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 972-986.	1.7	7
15	Intellectual disability associated with craniofacial dysmorphism, cleft palate, and congenital heart defect due to a <i>de novo</i> <i>MEIS2</i> mutation: A clinical longitudinal study. <i>American Journal of Medical Genetics, Part A</i> , 2021, 185, 1216-1221.	0.7	9
16	Protein signature of human skin fibroblasts allows the study of the molecular etiology of rare neurological diseases. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 73.	1.2	18
17	Molecular pathophysiology of human <i>MICU1</i> deficiency. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 840-855.	1.8	15
18	<i>INPP5K</i> and <i>SIL1</i> associated pathologies with overlapping clinical phenotypes converge through dysregulation of <i>PHGDH</i> . <i>Brain</i> , 2021, 144, 2427-2442.	3.7	7

#	ARTICLE	IF	CITATIONS
19	Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. <i>Nature Medicine</i> , 2021, 27, 1197-1204.	15.2	96
20	Exome reanalysis and proteomic profiling identified TRIP4 as a novel cause of cerebellar hypoplasia and spinal muscular atrophy (PCH1). <i>European Journal of Human Genetics</i> , 2021, 29, 1348-1353.	1.4	10
21	Muscular and Molecular Pathology Associated with SPATA5 Deficiency in a Child with EHLMRS. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7835.	1.8	4
22	Dysregulation of GSK3 $\beta$ -Target Proteins in Skin Fibroblasts of Myotonic Dystrophy Type 1 (DM1) Patients. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 603-619.	1.1	2
23	Clinical Course, Myopathology and Challenge of Therapeutic Intervention in Pediatric Patients with Autoimmune-Mediated Necrotizing Myopathy. <i>Children</i> , 2021, 8, 721.	0.6	7
24	Autosomal recessive variants in TUBGCP2 alter the $\beta$ -tubulin ring complex leading to neurodevelopmental disease. <i>iScience</i> , 2021, 24, 101948.	1.9	6
25	Intracellular Lipid Accumulation and Mitochondrial Dysfunction Accompanies Endoplasmic Reticulum Stress Caused by Loss of the Co-chaperone DNAJC3. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 710247.	1.8	13
26	Homozygous WASHC4 variant in two sisters causes a syndromic phenotype defined by dysmorphisms, intellectual disability, profound developmental disorder, and skeletal muscle involvement. <i>Journal of Pathology</i> , 2021, , .	2.1	5
27	Three Individuals with PURA Syndrome in a Cohort of Patients with Neuromuscular Disease. <i>Neuropediatrics</i> , 2021, 52, 390-393.	0.3	7
28	Noninvasive Imaging in Pediatric Spinal Muscular Atrophy Patients Using Multispectral Optoacoustic Tomography: A Proof-of-Concept Study. <i>Neuropediatrics</i> , 2021, 52, .	0.3	0
29	Phenotypical and Myopathological Consequences of Compound Heterozygous Missense and Nonsense Variants in SLC18A3. <i>Cells</i> , 2021, 10, 3481.	1.8	1
30	Severe neurodevelopmental disease caused by a homozygous TLK2 variant. <i>European Journal of Human Genetics</i> , 2020, 28, 383-387.	1.4	6
31	Clinical presentation and proteomic signature of patients with <i>TANGO2</i> mutations. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 297-308.	1.7	43
32	Further evidence for POMK as candidate gene for WWS with meningoencephalocele. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 242.	1.2	4
33	Long Term Follow-Up on Pediatric Cases With Congenital Myasthenic Syndromes – A Retrospective Single Centre Cohort Study. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 560860.	1.0	14
34	Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2020, 7, 231-246.	1.1	20
35	Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development. <i>Lancet Neurology</i> , The, 2020, 19, 522-532.	4.9	36
36	Immunofluorescence-Based Analysis of Caveolin-3 in the Diagnostic Management of Neuromuscular Diseases. <i>Methods in Molecular Biology</i> , 2020, 2169, 197-216.	0.4	5

#	ARTICLE	IF	CITATIONS
37	Modulation of the Acetylcholine Receptor Clustering Pathway Improves Neuromuscular Junction Structure and Muscle Strength in a Mouse Model of Congenital Myasthenic Syndrome. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 594220.	1.4	5
38	Modulation of Agrin and RhoA Pathways Ameliorates Movement Defects and Synapse Morphology in MYO9A-Depleted Zebrafish. <i>Cells</i> , 2019, 8, 848.	1.8	10
39	Identification of Cellular Pathogenicity Markers for SIL1 Mutations Linked to Marinesco-Sjögren Syndrome. <i>Frontiers in Neurology</i> , 2019, 10, 562.	1.1	5
40	Proteomic Profiling Unravels a Key Role of Specific Macrophage Subtypes in Sporadic Inclusion Body Myositis. <i>Frontiers in Immunology</i> , 2019, 10, 1040.	2.2	17
41	Identification of Candidate Protein Markers in Skeletal Muscle of Laminin-211-Deficient CMD Type 1A-Patients. <i>Frontiers in Neurology</i> , 2019, 10, 470.	1.1	14
42	SIL1 deficiency causes degenerative changes of peripheral nerves and neuromuscular junctions in fish, mice and human. <i>Neurobiology of Disease</i> , 2019, 124, 218-229.	2.1	7
43	The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes. <i>Human Molecular Genetics</i> , 2018, 27, 1556-1564.	1.4	28
44	MYO9A deficiency in motor neurons is associated with reduced neuromuscular agrin secretion. <i>Human Molecular Genetics</i> , 2018, 27, 1434-1446.	1.4	14
45	Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy-like disease. <i>Genetics in Medicine</i> , 2018, 20, 1224-1235.	1.1	31
46	Mutations in glycyI-tRNA synthetase impair mitochondrial metabolism in neurons. <i>Human Molecular Genetics</i> , 2018, 27, 2187-2204.	1.4	26
47	PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 870-878.	0.9	16
48	Clinical and research strategies for limb-girdle congenital myasthenic syndromes. <i>Annals of the New York Academy of Sciences</i> , 2018, 1412, 102-112.	1.8	17
49	Multifocal demyelinating motor neuropathy and hamartoma syndrome associated with a de novo <i>PTEN</i> mutation. <i>Neurology</i> , 2018, 90, e1842-e1848.	1.5	4
50	Tracking Effects of SIL1 Increase: Taking a Closer Look Beyond the Consequences of Elevated Expression Level. <i>Molecular Neurobiology</i> , 2018, 55, 2524-2546.	1.9	15
51	Mass spectrometry-based protein analysis to unravel the tissue pathophysiology in Duchenne muscular dystrophy. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700071.	0.8	26
52	Intersection of Proteomics and Genomics to Solve the Unsolved in Rare Disorders such as Neurodegenerative and Neuromuscular Diseases. <i>Proteomics - Clinical Applications</i> , 2018, 12, 1700073.	0.8	33
53	Neuromuscular Junction Changes in a Mouse Model of Charcot-Marie-Tooth Disease Type 4C. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4072.	1.8	24
54	Comprehensive RNA-Sequencing Analysis in Serum and Muscle Reveals Novel Small RNA Signatures with Biomarker Potential for DMD. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 1-15.	2.3	41

#	ARTICLE	IF	CITATIONS
55	Biochemical and pathological changes result from mutated Caveolin-3 in muscle. <i>Skeletal Muscle</i> , 2018, 8, 28.	1.9	19
56	GFPT1 deficiency in muscle leads to myasthenia and myopathy in mice. <i>Human Molecular Genetics</i> , 2018, 27, 3218-3232.	1.4	18
57	Mutations in INPP5K , Encoding a Phosphoinositide 5-Phosphatase, Cause Congenital Muscular Dystrophy with Cataracts and Mild Cognitive Impairment. <i>American Journal of Human Genetics</i> , 2017, 100, 523-536.	2.6	67
58	Intragenic <i>DOK7</i> deletion detected by whole-genome sequencing in congenital myasthenic syndromes. <i>Neurology: Genetics</i> , 2017, 3, e152.	0.9	4
59	Muscle Pathology as a Diagnostic Clue to Allgrove Syndrome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 337-341.	0.9	13
60	MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide. <i>Neuromuscular Disorders</i> , 2017, 27, 1054-1064.	0.3	15
61	The Caveolin-3 G56S sequence variant of unknown significance: Muscle biopsy findings and functional cell biological analysis. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600007.	0.8	6
62	Cellular Signature of SIL1 Depletion: Disease Pathogenesis due to Alterations in Protein Composition Beyond the ER Machinery. <i>Molecular Neurobiology</i> , 2016, 53, 5527-5541.	1.9	30
63	Inverted formin 2-related Charcot-Marie-Tooth disease: extension of the mutational spectrum and pathological findings in Schwann cells and axons. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 52-59.	1.4	21
64	Myopathy in Marinesco-Sjögren syndrome links endoplasmic reticulum chaperone dysfunction to nuclear envelope pathology. <i>Acta Neuropathologica</i> , 2014, 127, 761-777.	3.9	51
65	SIL1-negative Marinesco-Sjögren syndrome: First report of two sibs from India. <i>Journal of Pediatric Neurosciences</i> , 2014, 9, 291.	0.2	2
66	SH3TC2, a protein mutant in Charcot-Marie-Tooth neuropathy, links peripheral nerve myelination to endosomal recycling. <i>Brain</i> , 2010, 133, 2462-2474.	3.7	82